A study published in The Lancet indicates that semaglutide, a drug primarily used for weight loss, may also help individuals with obesity and alcohol dependence reduce their alcohol consumption. Conducted by Professor Anders Fink-Jensen from the Copenhagen Research Centre for Mental Health, the study involved 108 participants who received either semaglutide or a placebo alongside psychotherapy for alcohol use disorder. Results showed that those treated with semaglutide reduced their heavy drinking days from an average of 17 days to five days per month, compared to nine days in the placebo group. The treatment also led to fewer overall drinking days and lower cravings for alcohol. Given that alcohol use disorder contributes to 5% of deaths worldwide, these findings underscore the urgent need for new treatment options. Experts like Dr. Anoop Misra emphasize the dual challenge of obesity and alcohol misuse, particularly in urban areas of India, suggesting that semaglutide could provide a beneficial therapeutic approach. The potential reduction in the drug's price after patent expiration could further enhance accessibility for those in need.